Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $23.3 million.

  • Viking Therapeutics' Other Accumulated Expenses rose 3604.7% to $23.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $23.3 million, marking a year-over-year increase of 3604.7%. This contributed to the annual value of $23.3 million for FY2025, which is 3604.7% up from last year.
  • According to the latest figures from Q4 2025, Viking Therapeutics' Other Accumulated Expenses is $23.3 million, which was up 3604.7% from $21.2 million recorded in Q3 2025.
  • Viking Therapeutics' 5-year Other Accumulated Expenses high stood at $27.2 million for Q1 2024, and its period low was $7.3 million during Q4 2021.
  • For the 5-year period, Viking Therapeutics' Other Accumulated Expenses averaged around $13.7 million, with its median value being $11.3 million (2023).
  • Per our database at Business Quant, Viking Therapeutics' Other Accumulated Expenses surged by 23831.86% in 2024 and then plummeted by 5821.82% in 2025.
  • Quarter analysis of 5 years shows Viking Therapeutics' Other Accumulated Expenses stood at $7.3 million in 2021, then surged by 79.52% to $13.1 million in 2022, then fell by 13.84% to $11.3 million in 2023, then surged by 51.44% to $17.1 million in 2024, then surged by 36.05% to $23.3 million in 2025.
  • Its Other Accumulated Expenses was $23.3 million in Q4 2025, compared to $21.2 million in Q3 2025 and $26.0 million in Q2 2025.